457 related articles for article (PubMed ID: 10721812)
1. Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarization.
Aupetit JF; Bui-Xuan B; Kioueh I; Loufoua J; Frassati D; Timour Q
Can J Physiol Pharmacol; 2000 Mar; 78(3):208-16. PubMed ID: 10721812
[TBL] [Abstract][Full Text] [Related]
2. Disappearance with ischaemic depolarization of the antifibrillatory activity in a sodium channel blocker and appearance in calcium channel blocker.
Bui-Xuan B; Aupetit JF; Freysz M; Loufoua-Moundanga J; Faucon G; Timour Q
Arch Int Pharmacodyn Ther; 1996; 331(3):246-62. PubMed ID: 9124997
[TBL] [Abstract][Full Text] [Related]
3. [Value of calcium channel blockers in the prevention of ventricular fibrillation of ischemic etiology: experimental arguments].
Timour Q; Freysz M; Aupetit JF; Loufoua J; Frassati D; Faucon G
Bull Acad Natl Med; 1996 Jan; 180(1):215-26; discussion 226-7. PubMed ID: 8696877
[TBL] [Abstract][Full Text] [Related]
4. Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation.
Aupetit JF; Loufoua-Moundanga J; Faucon G; Timour Q
Br J Pharmacol; 1997 Feb; 120(3):523-9. PubMed ID: 9031759
[TBL] [Abstract][Full Text] [Related]
5. Prevention by calcium antagonists of profibrillatory effects of class I antiarrhythmic drugs in acute myocardial ischemia: study in pig heart in situ.
Bui-Xuan B; Aupetit JF; Freysz M; Faucon G; Timour Q
Pharmacotherapy; 1997; 17(4):737-45. PubMed ID: 9250551
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a beta-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: dependence on heart rate and ischaemia duration.
Aupetit JF; Frassati D; Bui-Xuan B; Freysz M; Faucon G; Timour Q
Cardiovasc Res; 1998 Mar; 37(3):646-55. PubMed ID: 9659448
[TBL] [Abstract][Full Text] [Related]
7. [Comparative study of different classes of anti-arrhythmia agents on the vulnerability of ischemic ventricular fibrillation].
Aupetit JF; Timour Q; Chevrel G; Omar S; Loufoua-Moundanga J; Faucon G
Therapie; 1993; 48(4):403-7. PubMed ID: 8128424
[TBL] [Abstract][Full Text] [Related]
8. [Arrhythmogenic risk of antiarrhythmic drugs: study with class Ic drugs during myocardial ischemia].
Faucon G; Aupetit JF; Gerentes-Chassagne I; Loufoua-Moundanga J; Larbre JP; Timour Q
Bull Acad Natl Med; 1991 Feb; 175(2):217-24; discussion 224-5. PubMed ID: 1907520
[TBL] [Abstract][Full Text] [Related]
9. Vulnerability to ventricular fibrillation related to ischaemia: comparison of the acute effects of beta-blockers and calcium antagonists.
Aupetit JF; Timour Q; Freysz M; Loufoua-Moundanga J; Omar S; Chevrel G; Faucon G
Arch Int Pharmacodyn Ther; 1994; 327(1):25-39. PubMed ID: 7944825
[TBL] [Abstract][Full Text] [Related]
10. Change of a beneficial effect into an untoward effect by ischaemia: effect of quinidine-like drugs on vulnerability to ventricular fibrillation.
Aupetit JF; Freysz M; Faucon G; Loufoua J; Timour Q
Environ Toxicol Pharmacol; 1996 Aug; 2(1):1-7. PubMed ID: 21781694
[TBL] [Abstract][Full Text] [Related]
11. Calcium antagonists and prevention of ventricular fibrillation induced by transient or persistent ischemia.
Timour Q; Bui-Xuan B; Aupetit JF; Freysz M; Evreux JC; Faucon G
Jpn Heart J; 1997 Mar; 38(2):237-51. PubMed ID: 9201111
[TBL] [Abstract][Full Text] [Related]
12. Further investigations into the mechanism of antifibrillatory action of the specific IK1 blocker, RP58866, assessed using the rat dual coronary perfusion model.
Rees SA; Curtis MJ
J Mol Cell Cardiol; 1995 Dec; 27(12):2595-606. PubMed ID: 8825880
[TBL] [Abstract][Full Text] [Related]
13. [Demonstration of the fibrillatory effect of class I anti-arrhythmia agents based on the time of fibrillation onset and electrical threshold in myocardial ischemia].
Timour Q; Aupetit JF; Loufoua-Moundanga JL; Barral-Cadière L; Freysz M; Faucon G
Therapie; 1994; 49(4):349-53. PubMed ID: 7878603
[TBL] [Abstract][Full Text] [Related]
14. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
[TBL] [Abstract][Full Text] [Related]
15. Inadequate ischaemia-selectivity limits the antiarrhythmic efficacy of mibefradil during regional ischaemia and reperfusion in the rat isolated perfused heart.
Farkas A; Qureshi A; Curtis MJ
Br J Pharmacol; 1999 Sep; 128(1):41-50. PubMed ID: 10498833
[TBL] [Abstract][Full Text] [Related]
16. Calcium channel modulators and susceptibility to ischaemic ventricular fibrillation: modification of cellular calcium overload.
Timour Q; Larbre JP; Kioueh I; Aupetit JF; Loufoua-Moundanga J; Vialle A; Faucon G
Arch Int Pharmacodyn Ther; 1992; 315():30-46. PubMed ID: 1384452
[TBL] [Abstract][Full Text] [Related]
17. A possible involvement of sodium channel blockade of class-I-type antiarrhythmic agents in postischemic contractile recovery of isolated, perfused hearts.
Takeo S; Tanonaka K; Hayashi M; Yamamoto K; Liu JX; Kamiyama T; Yamaguchi N; Miura A; Natsukawa T
J Pharmacol Exp Ther; 1995 Jun; 273(3):1403-9. PubMed ID: 7791114
[TBL] [Abstract][Full Text] [Related]
18. Symposium on the management of ventricular dysrhythmias. Antifibrillatory versus antiectopic therapy.
Anderson JL
Am J Cardiol; 1984 Jul; 54(2):7A-13A. PubMed ID: 6147079
[TBL] [Abstract][Full Text] [Related]
19. Magnesium--a profibrillatory or antifibrillatory drug depending on plasma concentration, heart rate and myocardial perfusion.
Aupetit JF; Freysz M; Faucon G; Loufoua-Moundanga J; Coquelin H; Timour Q
Acta Anaesthesiol Scand; 1997 Apr; 41(4):516-23. PubMed ID: 9150782
[TBL] [Abstract][Full Text] [Related]
20. [New aspects of the electrophysiologic effect of antiarrhythmic agents].
Antoni H; Weirich J
Herz; 1990 Apr; 15(2):61-9. PubMed ID: 2188893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
